LBCTR2022074978尚未招募2 期
A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of FT-4202 in Patients with Thalassemia or Sickle Cell Disease
Forma Therapeutics0 个研究点目标入组 60 人开始时间: 2022年9月8日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 12 至 65（—）
- 性别
- All
入选标准
- •Inclusion Criteria - All Cohorts
- •Informed Consent
- •1.Patient has provided documented informed consent or assent (the informed consent form [ICF] must be reviewed and signed by each patient; in the case of adolescent patients, both the consent of the patient’s legal representative or legal guardian, and the patient’s assent must be obtained)
- •2.Age 12 to 65 years, inclusive, at time of first dose
- •Sex and Contraceptive/Barrier Requirements
- •3.Patients, who if female and of childbearing potential, are using highly effective methods of contraception and agree not to donate ova from study start to 90 days after the last dose of study drug, and who if male are willing to use barrier methods of contraception and agree not to donate sperm, from study start to 90 days after the last dose of study drug.
- •Inclusion Criteria – Cohort Specific
- •Cohort A (SCD Transfusion Cohort)
- •1.Male or female study patient with a confirmed diagnosis of sickle cell disease
- •?Documentation of SCD genotype (HbSS, HbSß0-thalassemia or other sickle cell syndrome variants) may be based on history of laboratory testing or must be confirmed by laboratory testing during Screening
- •2.Chronically RBC transfused for primary stroke prevention or due to previous stroke.
- •Chronic RBC transfusion is defined as: = 6 RBC units in the previous 24 weeks before the first dose of study treatment and no transfusion-free period for > 35 days during that period
- •3.Receiving chronic RBC transfusion by straight transfusions
- •4.At least 24 months of chronic monthly RBC transfusions for primary stroke prevention or treatment of primary stroke (initial completed overt clinical stroke with document infarction on brain computed tomography [CT] or magnetic resonance imaging [MRI])
- •5.On iron chelation therapy for > 3 months prior to enrollment
- •6.Documented adequate monthly transfusions with average HbS = 45% (the upper limit of the established academic community standard) for the previous 12 weeks of RBC transfusions before the first dose of study treatment
- •Cohort B (Thalassemia Transfusion Cohort)
- •1. Male or female study patients with documented diagnosis of ß-thalassemia, Hemoglobin E/ ß-thalassemia or Hemoglobin H (a-thalassemia)
- •2. Chronically transfused, defined as: = 6 RBC units in the previous 24 weeks before the first dose of study treatment and no transfusion-free period for > 35 days during that period
- •3. On iron chelation therapy for > 3 months prior to enrollment
- •Cohort C (Thalassemia Non-transfused Cohort)
- •1. Male or female study patients with documented diagnosis of ß-thalassemia, Hemoglobin E/ ß-thalassemia or Hemoglobin H (a-thalassemia)
- •2. Hemoglobin = 10 g/dL
排除标准
- •Exclusion Criteria – All Cohorts
- •Medical Conditions
- •1.Female who is breast feeding or pregnant
- •2.Hepatic dysfunction characterized by:
- •?Alanine aminotransferase (ALT) > 4.0 × upper limit of normal (ULN)
- •?Direct bilirubin > 3.0 × ULN
- •?History of cirrhosis
- •3.Patients with clinically significant and active bacterial, fungal, parasitic, or viral infection.
- •?Patients with acute bacterial, fungal, parasitic, or viral infection requiring
- •systemic therapy should delay Screening/ enrollment until active therapy has been completed.
- •?Patients with acute viral infections without available therapies (eg, coronavirus disease 2019 [COVID-19]) should delay Screening/ enrollment until the acute infection has resolved.
- •Note: Infection prophylaxis is allowed (see concomitant medication restrictions).
- •4.Known human immunodeficiency virus (HIV) positivity
- •5.Active infection with hepatitis B virus (hepatitis B surface antigen [HepBsAg] and hepatitis B core antibody [HepBcAb] positive)
- •6.Active hepatitis C infection
- •7.Severe renal dysfunction (estimated glomerular filtration rate at the Screening visit;
- •calculated by the local laboratory < 30 mL/min/1.73 m2) or on chronic dialysis.
- •8.History of malignancy within the past 2 years prior to treatment Day 1 requiring systemic chemotherapy and/or radiation.
- •?Patients with malignancy considered surgically cured are eligible (eg, non- melanoma skin cancer, cancer of the cervix in-situ, ductal carcinoma in situ [Stage 1], Grade 1 endometrial cancer)
- •9.History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:
- •?Unstable angina pectoris or myocardial infarction or elective coronary intervention
- •?Heart disease, heart failure as classified by the New York Heart Association
- •(NYHA) classification 3 or higher, or significant arrhythmia requiring treatment,
- •?Pulmonary fibrosis or pulmonary hypertension which are clinically significant ie,
- •= Grade 3 National Cancer Institute (NCI) Common Terminology Criteria for
- •Adverse Events (CTCAE) version 4.0 (or higher)
- •10. Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable).
- •Prior/Concomitant Therapy
- •11. Chronic systemic glucocorticoids = 3 months (90 Days) prior to the first dose of study treatment (physiologic replacement therapy for adrenal insufficiency is allowed). Single day glucocorticoid treatment (eg, for prevention or treatment of transfusion reactions, is allowed).
- •12. Receiving or use of concomitant medications that are strong inducers or moderate/strong inhibitors of cytochrome P450 (CYP)3A4/5 within 2 weeks of starting study treatment or anticipated need for such agents during the study.
- •13. Use of erythropoietin or other hematopoietic growth factor treatment within 30 days of starting study treatment or anticipated need for such agents during the study.
- •14. Receipt of prior cellular-based therapy (eg, hematopoietic cell transplant, gene modification therapy)
- •15. Initiation of a new chelation therapy within 3 months before the first dose of study treatment
- •Prior/Concurrent Clinical Study Experience
- •16. Participated in another clinical trial of an investigational agent (or medical device) within
- •30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently
研究者
相似试验
招募中
1 期
Study to evaluate the safety and the activity of the drug FT-4202 in patients with blood genetic disordersEUCTR2021-005267-48-ITFORMA THERAPEUTICS, INC.60
尚未招募
2 期
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without DialysisPrimary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)Kidney DiseasesUrologic DiseasesGenetic DiseaseT51.2LBCTR2022125202Dicerna Pharmaceuticals30
进行中（未招募）
1 期
Study for patients with Primary Hyperoxaluria and Severe Renal Impairment to evaluate the efficacy, safety and tolerability of DCR-PHXCEUCTR2020-002826-97-FRDicerna Pharmaceuticals Inc24
进行中（未招募）
1 期
Study for patients with Primary Hyperoxaluria and Severe Renal Impairment to evaluate the efficacy, safety and tolerability of DCR-PHXCPrimary HyperoxaluriaMedDRA version: 20.1Level: PTClassification code 10020703Term: HyperoxaluriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2020-002826-97-ITDicerna Pharmaceuticals Inc.24
进行中（未招募）
1 期
Study for patients with Primary Hyperoxaluria and Severe Renal Impairment to evaluate the efficacy, safety and tolerability of DCR-PHXCEUCTR2020-002826-97-DEDicerna Pharmaceuticals Inc. (a Novo Nordisk Company)28